Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. - Wikidata - awgldk - TriplyDB

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

http://www.wikidata.org/entity/Q34159334

about

Targeted therapies and immunotherapy in non-small-cell lung cancer New targeted treatments for non-small-cell lung cancer - role of nivolumab Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC Gene aberrations for precision medicine against lung adenocarcinoma Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer The distinctive nature of adenocarcinoma of the lung The Evolution of Therapies in Non-Small Cell Lung Cancer Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer The minority report: targeting the rare oncogenes in NSCLC Cabozantinib for progressive metastatic medullary thyroid cancer: a review Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics 50 Years of progress in the systemic therapy of non-small cell lung cancer Targeted therapies in development for non-small cell lung cancer Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.Genomics driven-oncology: challenges and perspectives Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR Comprehensive molecular profiling of lung adenocarcinoma.From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience.Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade.The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.The Use of Non-Variant Sites to Improve the Clinical Assessment of Whole-Genome Sequence Data.Beyond histology: translating tumor genotypes into clinically effective targeted therapies.Fluorescence in situ hybridization in surgical pathology: principles and applications.Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.Molecular pathways and therapeutic targets in lung cancer Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel RET fusion gene: translation to personalized lung cancer therapy Molecular Testing of Lung Cancers Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma

P2860

Q26738986-28D916C4-C53B-4B50-843A-37343443E722 Q26740988-049D09C4-EE23-4FE5-93E9-8119DDF4F90E Q26747276-02A02CA3-D75C-4A1A-A951-8EED23596646 Q26749348-23A2E01D-ABA6-4D04-B7BF-E26EBCB38AC2 Q26768158-6B2454C4-6A1D-4899-AEA4-5FE1C5287565 Q26771116-D151F8CB-DFE5-4C6A-AD3D-30076E49B70B Q26781159-C3A02C68-1B41-4D59-96C6-DD70702F31BA Q26786932-534964DB-42AE-4E28-B9DA-D6623430A278 Q26799467-8820131C-1B8B-4BB0-AFCF-11E2C808887F Q26851421-57730788-AE44-429C-9184-26EC563A2850 Q26851636-43817877-0043-4A0D-8217-B79188838430 Q26851709-DFD24B8D-701F-4741-A042-13A039CB5A90 Q26864332-94AD064D-77F2-4A3E-A606-C4CD9AD53C40 Q27014978-BB3FB2DF-89A9-4753-9D7F-993F54E3FBDA Q27022852-CE9BB889-2487-47CA-B3A8-6E1B287D4766 Q27023383-4BBA3E75-D24E-4863-B216-4A8DF2CA7B5B Q27024233-425792AF-EC3D-44D4-B5B8-0F50F077A1E6 Q27025970-5B6D7C79-6320-458E-9285-FED1659623BF Q27027957-3301DF17-9121-4741-92A4-7EADD30925D2 Q27852601-42C2BF8B-D05A-4118-A9AF-C0807637A5E8 Q27853012-86B8BB43-D7E0-48DB-B306-87AD0013549A Q27853074-15B41050-2DE6-4FD0-B7FA-B8AFFF17943A Q27853306-BC989585-9C37-4C4B-9D17-C566DF12BDFA Q28081770-80BE624C-1492-4827-B5F7-D5256E6875D3 Q28083446-B78DBA41-2C97-4B51-A468-84B8D23EB750 Q28086993-8C14EBAB-3233-4E35-BEE5-A7E5D8FAA52A Q28244995-997F3E9C-49B7-483B-BD24-20311D0F6286 Q28385559-B3337301-1514-495B-8C35-E24F9BFE19EB Q28830947-14CD2FCF-D487-44FA-BD9F-AE38786CB881 Q30381368-6E6441F9-5958-4AE1-A346-A69F4C6762B9 Q30978835-BA7A3C3E-6373-4E41-ADEA-AD2041B4BA32 Q33560928-00474591-6B7F-4628-9F79-266B5B138694 Q33593910-AAE6FF92-6C18-4CCD-82D2-4BCE97B6A5A7 Q33688612-0C85404D-780E-4BBF-ACC5-92E67B71AC63 Q33688872-D4527A57-BABE-4E7F-AF01-2C9B3EA827E7 Q33699641-3001673C-FFFC-44F7-90AF-6FE8F9AB8F92 Q33711282-B64E176E-E226-4A52-8BFF-4FB0948DAFC1 Q33729715-91F2C1BE-FCC1-482B-982F-800471818C77 Q33906921-C5824B7D-A48A-4639-BB0C-ECE854892DD1 Q34073766-8D60BDF6-C285-4DF2-BF89-C57370D12B32

P2860

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

http://www.wikidata.org/entity/Q34159334

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@ast

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@en

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@nl

type

label

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@ast

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@en

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@nl

prefLabel

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@ast

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@en

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@nl

P1433

Q34159334-1FDE128B-DEAA-4FAD-AA1B-AEFC0BB48D4B

P1476

Q34159334-C7870434-FEAD-46C2-9052-545629BB3D12

P2093

Q34159334-107FF3E1-709E-42E2-A1D3-617D57C30F29

Q34159334-2F533EEE-B374-4A3C-BB79-4A486BC5E8DC

Q34159334-3792F4C6-8283-4C03-AB30-0F012C22CE38

Q34159334-5C5D6952-3028-4712-88D3-92DF5E0C820F

Q34159334-648501EC-876F-48C2-9560-F667BAC73334

Q34159334-865AEF23-D6AB-4B99-A9CB-1F1F35F13598

Q34159334-9DBF3E47-CF1A-4B51-A893-532576A7D4BF

Q34159334-AA8A73DA-873E-4151-89D4-A86C89CB74D1

Q34159334-BA81CE00-9DAF-4873-AD6B-CA8F8489E93D

Q34159334-BD3F6585-C6CA-4878-8F8F-7FA789D0C519

P2860

Q34159334-05CA9967-CC5F-44BD-A40E-3377046527B9

Q34159334-1529887B-AF42-4E6E-B6DD-74C885F2294A

Q34159334-330BAC98-3FCF-4E5B-A1EE-4ACA50DD8E42

Q34159334-3480CE0D-82DD-49A8-8BB6-63F1F570C17F

Q34159334-38E00D1D-5AE9-439B-BA9D-BF49E2A3AF44

Q34159334-3A300FDE-0732-40D0-A04B-501408BD7BDF

Q34159334-44501CF9-73EA-4B95-AA70-58D79C4E760C

Q34159334-5C60B84C-458C-4CBD-8794-268D5E8245B8

Q34159334-6C23BDDD-5CA5-4AB6-A3E0-04AEE4E1CCCC

Q34159334-7838F398-EBA7-4B2C-9712-00A3C9432937

P304

Q34159334-7DD57640-0DDF-4A11-81A2-BEFC02DEC6D4

P31

Q34159334-7ACB4A0D-A3F1-4E8E-B2D5-8412F1577143

P356

Q34159334-ED3F00CE-5D53-4CB3-A269-F7A040078E6F

P433

Q34159334-DC5BA26D-D54C-4802-A116-16DEFEBD9DA1

P478

Q34159334-6B64A272-F696-4AA4-BA11-5DA38C130E3C

P50

Q34159334-3C8D890A-88BB-40D3-828A-AD4E663DE41B

P577

Q34159334-CFB001C5-2E2B-4720-A4D4-7A8B518C9FAE

P698

Q34159334-241E9E37-7CDA-4919-B3C1-B82439BCAC61

P921

Q34159334-62919465-925D-4E75-B915-1BDFFCFD1D5B

P932

Q34159334-F5B03C40-CC57-46AE-BDC8-11180A043A7A

P356

2159-8290.CD-13-0035

P1433

Cancer Discovery

P1476

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

@en

P2093

Adnan Hasanovic

http://www.w3.org/2001/XMLSchema#string

Alexander Drilon

http://www.w3.org/2001/XMLSchema#string

Doron Lipson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Ross

http://www.w3.org/2001/XMLSchema#string

Lu Wang

http://www.w3.org/2001/XMLSchema#string

Mark G Kris

http://www.w3.org/2001/XMLSchema#string

Maureen F Zakowski

http://www.w3.org/2001/XMLSchema#string

Michelle Ginsberg

http://www.w3.org/2001/XMLSchema#string

Naiyer Rizvi

http://www.w3.org/2001/XMLSchema#string

Phil Stephens

http://www.w3.org/2001/XMLSchema#string

P2860

TIF1gamma, a novel member of the transcriptional intermediary factor 1 family

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

ROS1 rearrangements define a unique molecular class of lung cancers.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

The cancer genome

P304

630-635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-13-0035

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23533264

http://www.w3.org/2001/XMLSchema#string

P921

P932

4160032

http://www.w3.org/2001/XMLSchema#string